CPH News and Events

Resting heart rate measured with an investigational watch worn during the Project Baseline Health Study correlated strongly with electrocardiography (ECG), considered the gold standard.

A unique collaboration launched four years ago between CTSI and Durham Technical Community College continues to thrive and recently welcomed the latest cohort of the Clinical Research Equity Scholars Program.

Pulse oximetry has long been trusted as a key diagnostic tool. However, for patients with darker skin tones, this technology may not be accurate. A new grant aims to fix that.

Opeyemi Olabisi is among the 2025 researchers elected to the American Society for Clinical Investigation (ASCI), one of the nation’s oldest medical honor societies.

Using Genetic Tools to Prevent Disease

Affiliate Duke CTSI faculty members Keisha Bentley-Edwards, PhD, and Senthil Selvaraj, MD, have been named to the 2025 Office for Faculty leadership programs at Duke University School of Medicine.

Early in her career as a breast surgical oncology fellow, Hwang questioned the standard practice of treating patients diagnosed with ductal carcinoma in situ (DCIS) — a small cluster of abnormal cells in breast ducts — with mastectomies or lumpectomies, often followed by radiation.

The first study comparing surgery to active monitoring as treatment for ductal carcinoma in situ (DCIS) finds women who carefully monitor the precancerous cells are no more likely to develop breast cancer after two years than women who undergo surgery to remove them.

The Center for Precision Health has welcomed Opeyemi Olabisi, MD, PhD, associate professor of medicine.

Olabisi's research focuses on APOL1 variants that contribute to the progression of kidney disease. His ultimate goal is to translate his findings into improved diagnostic and treatment approaches for chronic kidney disease.

As a clinician, Olabisi cares for individuals with various degrees of kidney disease. He is passionate about raising awareness about kidney disease and introduce remedies that could slow the progression of kidney disease.

Currently, many patients receive inconclusive results from genetic testing, leaving them without a clear diagnosis or a path forward for treatment, but a new model developed by researchers at Duke University could help increase the number of patients receiving positive test results, providing them with valuable information that could guide treatment decisions. Results were published in Circulation: Genomic and Precision Medicine.